Moderna Stock Price, News & Analysis

Moderna, Inc. (Nasdaq: MRNA) has announced the dosing of the first participants in a Phase 2 clinical study for its modified COVID-19 vaccines, targeting potential booster candidates. The study includes mRNA-1273.351, focusing on the B.1.351 variant, and mRNA-1273.211, a multivalent candidate. With previous data showing some neutralization impact against variants, Moderna is strategically pursuing these developments. A Phase 1 trial by NIAID will commence post-FDA authorization, assessing the effectiveness of these vaccines in naïve individuals and as boosters.

Moderna (Nasdaq: MRNA) has been recognized as a leading company in Fast Company’s annual list of the World’s Most Innovative Companies for 2021, sharing the top spot with Pfizer-BioNTech. This accolade highlights the company's rapid development of the COVID-19 vaccine, created in less than a year, showcasing its commitment to mRNA technology and innovation. Moderna currently operates 24 mRNA development programs, with 13 in clinical studies. This recognition underscores Moderna’s impact on public health and its potential for future breakthroughs in various medical fields.

Baxter International and Moderna have entered an agreement for Baxter's BioPharma Solutions to manufacture and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021. The manufacturing will occur in Bloomington, Indiana, utilizing Baxter's 20 years of experience in vaccine production. This partnership aims to enhance Moderna's manufacturing capacity in the U.S., allowing for the expedited rollout of the vaccine to meet public health needs.

Moderna Inc. (Nasdaq: MRNA) announced the appointment of Shannon Thyme Klinger as Chief Legal Officer, effective June 1, 2021. Klinger, previously at Novartis, brings extensive experience in the pharmaceutical sector. CEO Stéphane Bancel highlighted her skills in corporate governance and compliance, which are essential for Moderna's expanding international presence. Klinger emphasized her commitment to innovation and public health. This transition follows the planned retirement of the current General Counsel, Lori Henderson, later in 2021.

Moderna (Nasdaq: MRNA) announced a supply agreement with the Philippine Government for 13 million doses of its COVID-19 Vaccine Moderna, with deliveries set to begin in mid-2021. The vaccine is currently not approved in the Philippines, and regulatory permissions are needed prior to distribution. Additionally, a prospective agreement for 7 million more doses involving the private sector is anticipated. CEO Stéphane Bancel expressed gratitude for the collaboration, emphasizing Moderna's commitment to combatting the pandemic through global vaccine availability.

Moderna (Nasdaq: MRNA) announced that Takeda Pharmaceutical (NYSE: TAK) submitted a New Drug Application (NDA) to the Japanese government for importing and distributing Moderna's COVID-19 vaccine candidate (mRNA-1273 or TAK-919). This NDA marks a significant step in the vaccine's clinical development in Japan. The Phase 1/2 study, involving 200 participants, is assessing the vaccine's safety and immunogenicity. Pending licensure, Takeda is set to distribute 50 million doses starting in the first half of 2021.

On March 4, 2021, Moderna and IBM announced plans to collaborate on technologies to enhance COVID-19 vaccine management. Their pilot program aims to improve supply chain visibility and real-time tracking of vaccine distribution, utilizing artificial intelligence, blockchain, and hybrid cloud technologies.

The initiative includes vaccine management solutions for secure data sharing between governments and healthcare providers, as well as a Digital Health Pass that allows individuals control over their health information, facilitating verification of vaccination status.

Moderna (MRNA) reported remarkable financial results for Q4 and FY 2020, achieving total revenue of $571 million for Q4 and $803 million for the full year, driven by COVID-19 vaccine sales and grants, a significant increase from $14 million and $60 million in 2019, respectively. As of December 31, 2020, cash reserves surged to $5.25 billion, up from $1.26 billion a year prior. Notably, the company increased its 2021 global manufacturing goal for its COVID-19 vaccine from 600 million to 700 million doses, with plans for 1.4 billion doses by 2022. Moderna's pipeline now includes 24 mRNA development programs, with 13 in clinical studies.

Moderna (MRNA) announced new capital investments to enhance its manufacturing capacity for the COVID-19 vaccine, targeting a global output of approximately 1.4 billion doses in 2022, assuming a 100 μg dosage. The flexibility to produce vaccine boosters for emerging variants is also a focus. The company has already increased its 2021 production plan from 600 million to 700 million doses, with ongoing efforts to optimize operations for up to 1 billion doses this fiscal year. Approximately 60 million doses have been shipped globally, with expectations to fulfill government contracts in 2021.